Northwell Health Walk Raises Record-setting $1.06M to Advance Health Care in Our Communities

More than 4,000 people comprising patients, families, community members and Northwell Health employees came together on May 21 to help raise more than $1.06 million for local hospital programs, breaking a record previously set in 2019. Supporters stepped up across five Northwell Health Walk locations – Jones Beach, Port Jefferson, Riverhead, Westchester and Staten Island – to raise funds in their respective communities for women and babies, cancer treatment, and child and adolescent behavioral health at Northwell Health hospitals.

“Every year, thousands of people across the region join the Northwell Health Walk to affirm their belief in Northwell’s commitment to raise health in our communities,” said Brian Lally, senior vice president and chief development officer for Northwell Health. “It’s extraordinary to see the outpouring of support that grows each and every year.”

A new mom’s journey inspires at Jones Beach

At Jones Beach, the festive day included appearances by Mr. & Mrs. Met and the Islanders’ Sparky the Dragon, a kids zone and face painting. Walkers warmed up to support mental healthcare programs and resources for pregnant and postpartum women at the Katz Institute for Women’s Health (KIWH) as well as plans for a new child and adolescent behavioral health hub at Cohen Children’s Medical Center.

Also participating in the Jones Beach Walk was Claire Byrnes of Northport, NY, who shared her pregnancy and childbirth story. After years of being told it would be impossible to carry a baby, Ms. Byrnes sought the help of KIWH obstetrician-gynecologist Stephanie McNally, MD, who helped her become pregnant. Dr. McNally worked with Cara Pessel, MD, a KIWH maternal-fetal specialist, to keep Mrs. Byrnes and the baby healthy. At 28 weeks, Mrs. Byrnes was admitted to the hospital with severe preeclampsia and extreme anxiety. Her son was born at three and a half pounds through an emergency delivery at 31 weeks and went home in less than two weeks. His grateful mother went home a few days later and continues to receive the help she needs for postpartum depression, anxiety and post-traumatic stress disorder through the Katz Institute.

“I am so grateful to my physicians at Northwell not only for making my dream of motherhood come true, but for their compassionate care in helping me cope with my postpartum mental health,” said Mrs. Byrnes, who was at the walk with her husband, John, and baby, Edward.  “This event is so important to raise funds so other women like me can have access to the expertise and resources they need to live healthy, fulfilled lives.”

Funds support the communities they serve

Across New York, funds raised at four other walks will support hospitals in their local communities. The Port Jefferson Walk supports the Fortunato Breast Cancer Center at Mather Hospital, and the East End/Riverhead Walk will help expand the breast health program and support the development of a comprehensive mother and baby unit at Peconic Bay Medical Center. Funds raised for Northern Westchester Hospital and Phelps Hospital will help with the purchase of sensory tools for young patients with autism and other challenges as well as support education and assistance programs for hospital team members. The Staten Island Walk supports the construction of the new Florina Cancer Center at Staten Island University Hospital.

The Walk began in 2010 as the “Every Woman Matters Walk,” inspired by the vision of philanthropists Iris and Saul Katz, whose commitment to high-quality health care continues to be felt throughout Northwell.  Since its inception, the Northwell Health Walk has raised more than $7 million and supports Northwell’s Outpacing the Impossible campaign, a comprehensive $1.4 billion fundraising effort that supports Northwell’s promise to the people it serves. The campaign’s objectives include improving hospitals and clinical programs, accelerating research and funding endowment.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”